INT81396

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.43
First Reported 1999
Last Reported 2010
Negated 4
Speculated 0
Reported most in Body
Documents 14
Total Number 14
Disease Relevance 10.73
Pain Relevance 0.74

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cell proliferation (ERBB2) signal transduction (ERBB2) plasma membrane (ERBB2)
nucleus (ERBB2) cytoplasm (ERBB2)
Anatomy Link Frequency
lymph node 4
ERBB2 (Homo sapiens)
Pain Link Frequency Relevance Heat
palliative 5 89.48 High High
Inflammation 23 86.76 High High
Pain 9 86.08 High High
agonist 8 77.32 Quite High
antagonist 18 74.88 Quite High
abdominal pain 2 64.08 Quite High
cva 5 58.00 Quite High
chemokine 198 50.00 Quite Low
cINOD 2 50.00 Quite Low
aspirin 2 10.00 Low Low
Disease Link Frequency Relevance Heat
Cancer 475 100.00 Very High Very High Very High
Breast Cancer 167 100.00 Very High Very High Very High
Ovarian Cancer 176 99.84 Very High Very High Very High
Apoptosis 104 99.00 Very High Very High Very High
Pancreatic Cancer 27 98.70 Very High Very High Very High
Adhesions 7 97.72 Very High Very High Very High
Death 7 97.00 Very High Very High Very High
Metastasis 67 95.16 Very High Very High Very High
Recurrence 16 94.44 High High
Hepatotoxicity 2 91.84 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
[Effects and costs of adjuvant chemotherapy for operable lymph node positive breast cancer with HER2/neu overexpression].
Regulation ([Effects) of Gene_expression (overexpression) of HER2/neu in lymph node associated with breast cancer
1) Confidence 0.43 Published 2006 Journal Ned Tijdschr Geneeskd Section Title Doc Link 16649394 Disease Relevance 0.37 Pain Relevance 0.07
[Effects and costs of adjuvant chemotherapy for operable lymph node positive breast cancer with HER2/neu overexpression].
Regulation ([Effects) of Gene_expression (overexpression) of HER2/neu in lymph node associated with breast cancer
2) Confidence 0.43 Published 2006 Journal Ned Tijdschr Geneeskd Section Title Doc Link 16649394 Disease Relevance 0.37 Pain Relevance 0.07
Alternatively, the tyrosine kinase inhibitor lapatinib provides single-agent targeting of both EGFR and HER2 [40, 41].
Regulation (targeting) of Gene_expression (agent) of HER2
3) Confidence 0.43 Published 2007 Journal Breast Cancer Res Treat Section Body Doc Link PMC2001220 Disease Relevance 0.41 Pain Relevance 0.04
Our results demonstrate that local therapy with scFv(FRP5)-ETA can be effective against ErbB2 expressing tumors justifying further clinical development of this reagent.
Regulation (effective) of Gene_expression (expressing) of ErbB2 associated with cancer
4) Confidence 0.43 Published 2003 Journal Breast Cancer Res. Treat. Section Abstract Doc Link 14703062 Disease Relevance 1.00 Pain Relevance 0.13
Pertuzumab inhibits the formation of the HER2 heterodimer, independent of HER2 expression levels, and its binding site does not overlap with the epitope on HER2 that is recognized by trastuzumab (Herceptin) (14,15).
Neg (independent) Regulation (independent) of Gene_expression (expression) of HER2
5) Confidence 0.39 Published 2009 Journal Japanese Journal of Clinical Oncology Section Body Doc Link PMC2661001 Disease Relevance 0.95 Pain Relevance 0.15
g/ml trastuzumab, did not have a significant effect on HER2 expression level or activity.
Regulation (effect) of Gene_expression (expression) of HER2
6) Confidence 0.29 Published 2010 Journal Breast Cancer Res Section Body Doc Link PMC2949655 Disease Relevance 0.33 Pain Relevance 0
M had no effect on HER2 expression level or the degree of phosphorylation, and, when added to 1 ?
Neg (no) Regulation (effect) of Gene_expression (expression) of HER2
7) Confidence 0.29 Published 2010 Journal Breast Cancer Res Section Body Doc Link PMC2949655 Disease Relevance 0.41 Pain Relevance 0
The transforming genetic lesions in these cells are not fully characterized, but do not seem to involve alterations in ErbB2 gene expression.
Regulation (alterations) of Gene_expression (expression) of ErbB2 gene
8) Confidence 0.27 Published 1999 Journal Hybridoma Section Abstract Doc Link 10211791 Disease Relevance 0.83 Pain Relevance 0
Expression of ErbB2 protein was largely unchanged by lapatinib.
Neg (unchanged) Regulation (unchanged) of Gene_expression (Expression) of ErbB2
9) Confidence 0.25 Published 2010 Journal Cancer management and research Section Body Doc Link PMC3004582 Disease Relevance 0.74 Pain Relevance 0
Pertuzumab inhibits the formation of the HER2 heterodimer, independent of HER2 expression levels, and its binding site does not overlap with the epitope on HER2 that is recognized by trastuzumab (Herceptin) (14,15).
Neg (independent) Regulation (independent) of Gene_expression (expression) of HER2
10) Confidence 0.24 Published 2009 Journal Japanese Journal of Clinical Oncology Section Body Doc Link PMC2661001 Disease Relevance 0.95 Pain Relevance 0.15
Aberrant EGFR and HER2 expression was reported in ovarian carcinomas [59].
Regulation (reported) of Gene_expression (expression) of HER2 associated with ovarian cancer
11) Confidence 0.19 Published 2010 Journal Journal of Oncology Section Body Doc Link PMC2798669 Disease Relevance 1.25 Pain Relevance 0
Nevertheless, it needs to take in account that, in this study, CXCR4 and HER2/neu expression was evaluated in paraffin-embedded tissues blocks and their histology and grading was related with survival of patients, without analysis of the metastatic sites.
Regulation (evaluated) of Gene_expression (expression) of HER2
12) Confidence 0.19 Published 2010 Journal Journal of Oncology Section Body Doc Link PMC2798669 Disease Relevance 1.60 Pain Relevance 0.04
Immunohistochemical assessment was performed for alterations in expression of Ki-67, erbB-2, COX enzyme, and apoptosis in primary ovarian cancer cells using terminal deoxynucleotidyl transferase (Tdt)-mediated nick end labeling assay.
Regulation (alterations) of Gene_expression (expression) of erbB-2
13) Confidence 0.18 Published 2002 Journal Clin. Cancer Res. Section Body Doc Link 11801560 Disease Relevance 0.09 Pain Relevance 0
There has been interest in using immunotherapy for pancreatic cancer based on the identification of mutated oncogenes, such as KRAS, altered tumor suppressor genes, such as TP53, CDKN2A, DPC4, BRCA2, and ERBB2, as well as over-expression of tumor-associated antigens, such as CEA and MUC-1, in pancreatic carcinoma cells [5].
Regulation (altered) of Gene_expression (expression) of ERBB2 associated with cancer and pancreatic cancer
14) Confidence 0.11 Published 2007 Journal J Transl Med Section Body Doc Link PMC2217514 Disease Relevance 1.42 Pain Relevance 0.09

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox